TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vivesto AB ( (SE:VIVE) ) just unveiled an announcement.
Vivesto AB held a live-streamed business update to discuss recent advancements in their oncology pipeline, highlighting positive interim results from the Paccal Vet clinical study in dogs and promising preclinical data for Cantrixil in hematological cancers. The update, featuring insights from both internal and external experts, outlined development plans and the commercial potential of these programs, emphasizing their impact on addressing unmet medical needs in both human and veterinary oncology.
More about Vivesto AB
Vivesto AB is a Swedish development company focused on oncology, aiming to provide new treatment options for hard-to-treat cancers with significant medical needs and market potential. Its project portfolio includes Cantrixil for blood cancer and Paccal Vet, a veterinary oncology program under evaluation in clinical trials for dogs and cats.
YTD Price Performance: -50.34%
Average Trading Volume: 681,253
Technical Sentiment Signal: Sell
Current Market Cap: SEK77.48M
Find detailed analytics on VIVE stock on TipRanks’ Stock Analysis page.